Icon

SINEQUAN (nda016798)- (EQ 25MG BASE,EQ 50MG BASE,EQ 10MG BASE,EQ 100MG BASE,EQ 75MG BASE,EQ 150MG BASE)

DOXEPIN HYDROCHLORIDE PFIZER
EQ 25MG BASE,EQ 50MG BASE,EQ 10MG BASE,EQ 100MG BASE,EQ 75MG BASE,EQ 150MG BASE
No No
Expired Expired
None None
None No
SINEQUAN is recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
25 0 21
Total Other Developers None
Drugs with Suitability No
EQ 25MG BASE ** ** - - 14
EQ 50MG BASE ** ** - - 14
EQ 10MG BASE ** ** - - 14
EQ 100MG BASE ** ** - - 14
EQ 75MG BASE ** ** - - 14
EQ 150MG BASE ** ** - - 2
NDA Sales Available Total Generic Sales Available
No 18
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** **** ** ***. *********** ** *** ****** **** ********** ****, *** **, ******, ****** **** (**) *****, ****** ****** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** **** ****** *** **** ******, *** *********** ***** ***** ******* ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** **** **** ************** ********** ***. *********** ** ******* ******, ***** ***, *******, ****** (***) ***
****** ****** ***** *** ******** ********* ****. *********** *** ******* *****, *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** ***** *** ******** ********* ****. *********** *** ******** *****, *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** ***** *** ******** ********* ****. *********** *** ******** *****, *********, *** **** (**) *****, ****** ****** (***) ***
****** ****** ***** *** ******** ********* ****. *********** *** **** ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** ***** ***** ****** *** *********** *** *** *** ********* ** ***** *, *, *-* & *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******** ******* ******** ******* *************** ***. *********** *** ***** *****, *********, ******** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ********* ** ********* *************** *******, ***. *********** ** ******* *****, *** ***** ******, *******, *** **** (**) *****, ****** ****** (***) ***
****** ***** ************ ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***
****** ****** ***** * * ********* *** *************** ******* *********** **** **. ***-***, *.*.*.* ********** ****, *******, ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** *-*\*\*, **** ****, *******, *********** *************, *********** ******, ***** (***) ***
****** ******* ********** *** *********** **** *****-***** **, **** ** ******, *****, *.*. *** *****, ****** **** ******** (***) ***
****** ****** ****** *** ********** *** *********** **** *****-***** **, **** ** ******, *****, *.*. *** *****, ****** **** ******** (***) ***
****** **** ********** *** ************ ******* ******* *********** */***, **********-******** **** ****, **********, ***********,,, *******, ***** **** ******, ***** (***) ***
****** ***** ************ ***** ************ ******* *********** ****** **. ***, *** *** ***, ******* ***** *. *. **. ** *******-*******, ******-****** *********, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.